HCPCS Level II code Q5120 designates injection of pegfilgrastim-bmez (Ziextenzo), a biosimilar pegfilgrastim product in a 0.5 mg presentation. This code is used when administering a therapeutic granulocyte colony-stimulating factor to reduce chemotherapy-associated febrile neutropenia risk, making it a clinically relevant item across oncology care settings nationwide. Payers commonly recognizing this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare.

Readers will find a concise overview of clinical context for biosimilar pegfilgrastim use, typical sites of service such as outpatient oncology infusion centers and physician offices, and coverage landscape considerations. The publication summarizes benchmarks and reimbursement themes for Q5120, highlights policy and coding updates that affect billing for biosimilar injectables, and outlines practical billing considerations tied to service line and claim submission. Clinical relevance is emphasized because use of biosimilars like pegfilgrastim-bmez can influence access to supportive cancer care and cost dynamics at a national level.

Data not available in the input for specific payor rates, associated taxonomies, ICD-10 pairings, or related codes.